Abstract
Sporozoite-based approaches currently represent the most effective vaccine strategies for induction of sterile protection against Plasmodium falciparum (Pf) malaria. Clinical development of subunit vaccines is almost exclusively centered on the circum-sporozoite protein (CSP), an abundantly expressed protein on the sporozoite membrane. Anti-CSP antibodies are able to block sporozoite invasion and development in human hepatocytes and subsequently prevent clinical malaria. Here, we have investigated whether sporozoite-induced human antibodies with specificities different from CSP can reduce Pf-liver stage development. IgG preparations were obtained from 12 volunteers inoculated with a protective immunization regime of whole sporozoites under chloroquine prophylaxis. These IgGs were depleted for CSP specificity by affinity chromatography. Recovered non-CSP antibodies were tested for sporozoite membrane binding and for functional inhibition of sporozoite invasion of a human hepatoma cell line and hepatocytes both in vitro and in vivo. Postimmunization IgGs depleted for CS specificity of 9 of 12 donors recognized sporozoite surface antigens. Samples from 5 of 12 donors functionally reduced parasite-liver cell invasion or development using the hepatoma cell line HC-04 and FRG-huHep mice containing human liver cells. The combined data provide clear evidence that non-CSP proteins, as yet undefined, do represent antibody targets for functional immunity against Pf parasites responsible for malaria.
Highlights
Malaria remains an enormous global challenge with 229 million new cases and 409.000 deaths reported in 2019
Plasma was selected from 12 volunteers who received 3 immunizations with PfNF54 sporozoites under chemoprophylaxis with chloroquine
We previously showed that chemoprophylaxis with sporozoite (CPS)-immune sera contain antibodies against a number of wellestablished targets including Circum-sporozoite Protein (CSP), liver stage antigen 1 (LSA-1), exported protein 1 (EXP-1), thrombospondin-related anonymous protein (TRAP), a 19kDa fragment of merozoite surface protein 1 (MSP-1) and the apical-membrane protein 1 (AMA-1)(21, 24)
Summary
Malaria remains an enormous global challenge with 229 million new cases and 409.000 deaths reported in 2019. Since 2015, the rate of progress to malaria eradication has slowed[1], evidencing the need to develop new and better tools. Sporozoites are extracellular, motile parasite forms that glide and migrate through the dermis to eventually enter the circulation and reach the liver[4]. During this journey of up to 2-3 hours, free sporozoites are vulnerable while exposed to the host immune system[3, 5]. After 7 days, asexual parasite forms are released into the circulation giving rise to clinical manifestations of malaria
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have